Sodium‐glucose co‐transporter‐2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: Anetwork and cumulative meta‐analysis of randomized controlled trials
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Aim: To compare the associations of individual sodium‐glucose co‐transporter ‐ 2 ( SGLT2 ) inhibitors with adverse renal outcomes in patients with type 2 diabetes mellitus ( T2DM ). Methods: PubMed , EMBASE , CENTRAL and ClinicalTrials.gov were searched for studies published up to M ay 24, 2016, without language or date restrictions. Randomized trials that reported at least 1 renal‐related adverse outcome in patients with T2DM treated with SGLT2 inhibitors were included. Pairwise and network meta‐analyses were carried out to calculate the odds ratios ( ORs ) with 95% confidence intervals ( CIs ), and a cumulative meta‐analysis was performed to assess the robustness of evidence. Results: In total, we extracted 1334 composite renal events among 39 741 patients from 58 trials, and 511 acute renal impairment/failure events among 36 716 patients from 53 trials. Dapagliflozin was significantly associated with a greater risk of composite renal events than placebo ( OR 1.64, 95% CI 1.26‐2.13). Empagliflozin seemed to confer a lower risk than placebo ( OR 0.63, 95% CI 0.54‐0.72), canagliflozin ( OR 0.48, 95% CI 0.29‐0.82) and dapagliflozin ( OR 0.38, 95% CI 0.28‐0.51). With regard to acute renal impairment/failure, only empagliflozin was significantly associated with a lower risk than placebo ( OR 0.72, 95% CI 0.60‐0.86). The cumulative meta‐analysis indicated the robustness of our significant findings. Conclusions: The present meta‐analysis indicated that dapagliflozin may increase the risk of adverse renal events, while empagliflozin may have a protective effect among patients with T2DM . Further data from large well‐conducted randomized controlled trials and a real‐world setting are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“The present review was performed according to the PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of healthcare interventions.(16)”
MethodEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473 · cited 1×
“0 using the “mvmeta” command and programmed STATA routines.(19,20) For a zeroevent RCT, a 0.”
MethodConsistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“To check the assumption of consistency in the entire network, a design-bytreatment interaction model using the chi-squared test was applied.(25) To test the robustness of the findings, we assessed the modulating effects of different trial and participant characteristics on primary outcomes of sensitivity analyses rest…”
MethodSalanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1037 · Cited by 1,729 · cited 1×
“For adverse renal outcomes, higher SUCRA probability and lower mean rank indicate a safer intervention.(22) The heterogeneity variance (tau) estimated by a restricted maximum likelihood method was employed to quantify between-study heterogeneity for each outcome.”
MethodWhite, I. R., Barrett, J. K., Jackson, D., & Higgins, J. P. T. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1045 · Cited by 1,114
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Turner, R. M., Davey, J., Clarke, M. J., Thompson, S. G., & Higgins, J. P. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys041 · Cited by 837 · cited 1×
“The heterogeneity variance (tau) estimated by a restricted maximum likelihood method was employed to quantify between-study heterogeneity for each outcome.(23)”
MethodDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652 · cited 2×
“reported that dapagliflozin was associated with an increased incidence of renal impairment or failure and creatinine increase or eGFR decrease in patients with T2DM, especially in elderly patients or those with extant renal impairment.(9,10,31) Evidence showed that elevated serum creatinine level or lowered eGFR retur…”
BackgroundEvaluation of inconsistency in networks of interventions
Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P., & Salanti, G. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys222 · Cited by 576 · cited 1×
“To check for possible inconsistency, a loop inconsistency-specific approach was introduced to evaluate the difference between direct and indirect estimates for a specific comparison.(24) To check the assumption of consistency in the entire network, a design-bytreatment interaction model using the chi-squared test was…”
MethodChaimani, A., & Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.57 · Cited by 521 · cited 1×
“Finally, a comparison-adjusted funnel plot was used to assess small-study effects within a network of interventions, with symmetry around the summary effect line indicating the absence of small-study effects.(27)”
MethodBaker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Cited by
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
“In a nationwide register-based cohort study, likewise, the incidence of AKI did not differ significantly between SGLT2i and GLP1-RA users [145].”
BackgroundInfluentialSodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Malhotra, R., Craven, T., Ambrosius, W. T., Killeen, A. A., Haley, W. E., Cheung, A. K., Chonchol, M., Sarnak, M., Parikh, C. R., Shlipak, M. G., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.07.015 · Cited by 132
on behalf of the Scottish Diabetes Research Network Epidemiology Group, McGurnaghan, S. J., Brierley, L., Caparrotta, T. M., McKeigue, P. M., Blackbourn, L. A. K., Wild, S. H., Leese, G. P., McCrimmon, R. J., McKnight, J. A., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4806-9 · Cited by 46
Shi, F.-H., Li, H., Shen, L., Zhang, Z., Jiang, Y.-H., Hu, Y.-M., Liu, X.-Y., Gu, Z.-C., Ma, J., & Lin, H.-W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01066 · Cited by 30
“With the widespread clinical use, the adverse effects, such as infection-related (Li et al., 2017; Liu et al., 2017; Puckrin et al., 2018) or renal-related adverse events (Perlman et al., 2017; Tang et al., 2017; Xu et al., 2017), had been raised.”
BackgroundResult
Metadata
- Authors
- Tang, H., Li, D., Zhang, J., Li, Y., Wang, T., Zhai, S., & Song, Y.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-31
- Volume
- 19
- Issue
- 8
- Pages
- 1106-1115
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2594305555
- Cited by
- 71
- References
- 15
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.